Novo Nordisk, the Denmark-based multinational pharmaceutical company best known as the world's largest insulin maker, may expand into the field of gene therapy, CEO Lars Fruergaard Jørgensen told Bloomberg on May 3.
Novo Nordisk is reportedly looking for potential acquisitions and partnerships to explore the use of gene therapy and editing to target genetic flaws that cause serious diseases. The company has already begun moving beyond insulin production by exploring new treatments for obesity, liver disease and hemophilia, and developing stem-cell therapies for Parkinson's disease.
"In the pharma industry, the more we can bring real breakthrough innovation, the better we're seen as contributing to society, so I'm very positive toward curative treatments," Mr. Jørgensen said.
More articles about health IT:
uBiome patients, insiders describe lab test startup's questionable practices
FBI approves advanced genomic DNA analysis for use in forensic labs
CAR T-cell gene therapy shows promising results in multiple myeloma patients